贝伐珠单抗在晚期低级别浆液性卵巢癌中的疗效：MITO 22 试验数据。

Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial.

机构信息

Department of Women and Child Health, Division of Gynecologic Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Department of Oncology, University of Torino at Ordine Mauriziano Hospital, Turin, Italy.

出版信息

Gynecol Oncol. 2023 May;172:72-77. doi: 10.1016/j.ygyno.2023.03.011. Epub 2023 Mar 23.

DOI:10.1016/j.ygyno.2023.03.011

PMID:36965291

Abstract

OBJECTIVE

The aim of the present analysis was to explore the efficacy of Bevacizumab (Bev) on survival outcome in advanced low grade serous ovarian cancer (LGSOC) both in first line and in recurrent setting.

METHODS

In retrospective observational multicenter study, we described the outcome of LGSOC patients enrolled in the MITO 22 study and treated with chemotherapy (CT) with or without Bev. Patients receiving Bev in first-line or in recurrence were considered and compared with patients receiving CT alone (stage III and IV in first line; platinum based-CT in second line). Descriptive and survival analyses were performed for each group.

RESULTS

Out of 128 patients included in MITO 22, 46 LGSOC patients receiving Bev in first line setting or at the time of first recurrence were identified. In first line, 30 patients received Bev + CT and 65 CT alone and the median PFS were 47.86 months (95% CI: 31.48 - NR) and 22.63 months (95% CI 15-39.24) (p-value 0.0392), respectively. In the recurrent setting, 16 patients who received Bev + CT were compared to 33 women treated with platinum-based CT alone. Median PFS were 37.1 months (95% CI: 13.42-40.56) and 11.22 months (95% CI: 8.26-15.63) (p-value 0.013), respectively.

CONCLUSIONS

Our study suggests that Bev might be effective in LGSOC both at diagnosis and at the time of relapse. These data warrants further studies.

摘要

目的

本分析旨在探讨贝伐珠单抗（Bev）在一线和复发性晚期低级别浆液性卵巢癌（LGSOC）中对生存结果的疗效。

方法

在回顾性观察性多中心研究中，我们描述了在 MITO 22 研究中入组并接受化疗（CT）联合或不联合 Bev 治疗的 LGSOC 患者的结局。接受一线或复发时接受 Bev 治疗的患者被考虑，并与单独接受 CT 治疗的患者（一线为 III 期和 IV 期；二线为铂类 CT）进行比较。对每个组进行描述性和生存分析。

结果

在 MITO 22 中纳入的 128 名患者中，确定了 46 名在一线治疗或首次复发时接受 Bev 治疗的 LGSOC 患者。一线治疗中，30 名患者接受 Bev+CT 治疗，65 名患者单独接受 CT 治疗，中位 PFS 分别为 47.86 个月（95%CI：31.48-NR）和 22.63 个月（95%CI 15-39.24）（p 值=0.0392）。在复发性疾病中，将 16 名接受 Bev+CT 治疗的患者与 33 名单独接受铂类 CT 治疗的患者进行比较。中位 PFS 分别为 37.1 个月（95%CI：13.42-40.56）和 11.22 个月（95%CI 8.26-15.63）（p 值=0.013）。